SG11201506113WA - Daptomycin formulations and uses thereof - Google Patents

Daptomycin formulations and uses thereof

Info

Publication number
SG11201506113WA
SG11201506113WA SG11201506113WA SG11201506113WA SG11201506113WA SG 11201506113W A SG11201506113W A SG 11201506113WA SG 11201506113W A SG11201506113W A SG 11201506113WA SG 11201506113W A SG11201506113W A SG 11201506113WA SG 11201506113W A SG11201506113W A SG 11201506113WA
Authority
SG
Singapore
Prior art keywords
daptomycin formulations
daptomycin
formulations
Prior art date
Application number
SG11201506113WA
Other languages
English (en)
Inventor
Jim Alexiou
Andrew Knill
Noel Norris
Darryl Whittaker
Original Assignee
Hospira Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50277707&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201506113W(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hospira Australia Pty Ltd filed Critical Hospira Australia Pty Ltd
Publication of SG11201506113WA publication Critical patent/SG11201506113WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
SG11201506113WA 2012-09-11 2013-09-11 Daptomycin formulations and uses thereof SG11201506113WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261699570P 2012-09-11 2012-09-11
US201361839699P 2013-06-26 2013-06-26
PCT/IB2013/002191 WO2014041425A1 (en) 2012-09-11 2013-09-11 Daptomycin formulations and uses thereof

Publications (1)

Publication Number Publication Date
SG11201506113WA true SG11201506113WA (en) 2015-09-29

Family

ID=50277707

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201506113WA SG11201506113WA (en) 2012-09-11 2013-09-11 Daptomycin formulations and uses thereof

Country Status (20)

Country Link
US (4) US9655946B2 (el)
EP (2) EP2895187A4 (el)
AU (2) AU2013316779A1 (el)
BR (1) BR112015005400B1 (el)
CA (1) CA2884484C (el)
CL (1) CL2015000608A1 (el)
CY (1) CY2200004T2 (el)
DE (1) DE13837694T1 (el)
DK (1) DK2895187T1 (el)
ES (1) ES2552754T1 (el)
HK (1) HK1207006A1 (el)
HU (1) HUE13837694T1 (el)
IL (1) IL237652B (el)
MX (1) MX366122B (el)
NZ (3) NZ706286A (el)
SA (1) SA515360129B1 (el)
SG (1) SG11201506113WA (el)
TN (1) TN2015000090A1 (el)
WO (1) WO2014041425A1 (el)
ZA (1) ZA201502310B (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
EP2895187A4 (en) * 2012-09-11 2015-12-02 Hospira Australia Pty Ltd DAPTOMYCIN FORMULATIONS AND USES THEREOF
EP3528786B1 (en) 2016-10-21 2023-04-05 Xellia Pharmaceuticals ApS Liquid formulations of daptomycin
MX2020001885A (es) 2017-08-31 2020-09-07 Xellia Pharmaceuticals Aps Formulaciones de daptomicina.
CN110339342A (zh) * 2018-04-03 2019-10-18 江苏恒瑞医药股份有限公司 一种达托霉素的盐或含盐的组合物及其制备方法
US11058745B1 (en) 2018-10-04 2021-07-13 Good Health, Llc Stable liquid pharmaceutical compositions of daptomycin
AU2021233893A1 (en) 2020-03-12 2022-08-25 Baxter Healthcare Sa Daptomycin formulations containing a combination of sorbitol and mannitol
IL300090A (en) 2020-07-24 2023-03-01 Genzyme Corp Pharmaceutical preparations containing VENGLUSTAT
CN115590825B (zh) * 2022-10-20 2024-02-02 安士制药（中山）有限公司 一种注射用达托霉素及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5560906A (en) * 1995-03-27 1996-10-01 Oral Technology Laboratories, Inc. Non-alcoholic antimicrobial mouthwash for removal of dental plaque
ATE322280T1 (de) * 1998-09-25 2006-04-15 Cubist Pharm Inc Verwendung von daptomycin
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
WO2002059145A1 (en) 2000-12-18 2002-08-01 Cubist Pharmaceuticals, Inc. Methods for preparing purified lipopeptides
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
CN1616083A (zh) * 2004-09-01 2005-05-18 魏雪纹 注射用达托霉素冻干制剂及制备方法
CA2610716A1 (en) * 2005-05-31 2006-12-07 Cubist Pharmaceuticals, Inc. Daptomycin for the treatment of biofilm and catheter salvage
NZ600118A (en) 2009-11-23 2014-08-29 Cubist Pharm Inc Lipopeptide compositions and related methods
JP2013511522A (ja) * 2009-11-23 2013-04-04 イーグル・ファーマシューティカルズ・インコーポレーテッド ダプトマイシン製剤
CA2881121A1 (en) * 2012-08-23 2014-03-27 Agila Specialties Private Limited Improved daptomycin injectable formulation
EP2895187A4 (en) * 2012-09-11 2015-12-02 Hospira Australia Pty Ltd DAPTOMYCIN FORMULATIONS AND USES THEREOF

Also Published As

Publication number Publication date
SA515360129B1 (ar) 2016-08-15
US20170216396A1 (en) 2017-08-03
ES2552754T1 (es) 2015-12-02
IL237652B (en) 2020-06-30
BR112015005400A2 (pt) 2017-07-04
HK1207006A1 (en) 2016-01-22
NZ742241A (en) 2019-08-30
US10357535B2 (en) 2019-07-23
ZA201502310B (en) 2019-09-25
DE13837694T1 (de) 2015-12-31
DK2895187T1 (da) 2015-11-16
EP4066849A1 (en) 2022-10-05
MX366122B (es) 2019-06-27
US20200237858A1 (en) 2020-07-30
TN2015000090A1 (en) 2016-06-29
EP2895187A1 (en) 2015-07-22
US20180177843A1 (en) 2018-06-28
CA2884484C (en) 2021-01-19
CY2200004T2 (el) 2016-02-10
CL2015000608A1 (es) 2015-11-06
IL237652A0 (en) 2015-04-30
HUE13837694T1 (hu) 2016-04-28
US9655946B2 (en) 2017-05-23
WO2014041425A1 (en) 2014-03-20
AU2013316779A1 (en) 2015-04-02
AU2018217322A1 (en) 2018-09-06
BR112015005400B1 (pt) 2022-03-08
EP2895187A4 (en) 2015-12-02
AU2018217322B2 (en) 2020-08-27
NZ706286A (en) 2018-05-25
NZ741342A (en) 2019-10-25
MX2015003164A (es) 2015-12-16
CA2884484A1 (en) 2014-03-20
US20150313958A1 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
IL252566A0 (en) Pharmacy preparations and methods
IL235436A0 (en) Anti-pcsk9 preparations and their use
HK1199023A1 (en) Substituted benzothienylpyrrolotriazines and uses thereof
HK1200822A1 (en) Substituted dipyridylamines and uses thereof
HK1210714A1 (en) Antibody formulations and uses thereof
HK1210949A1 (en) Combinations and uses thereof
HUE13837694T1 (hu) Daptomicin készítmények és alkalmazásaik
ZA201501124B (en) Trans-clomiphene formulations and uses thereof
AP2015008498A0 (en) Compositions comprising vortioxetine and donepezil
GB201315350D0 (en) Methods and compositions
EP2874641A4 (en) COMPOSITIONS INCREASING THE GLUTATHION RATE AND USES THEREOF
GB201315347D0 (en) Methods and compositions
HK1210809A1 (en) Beta-hexosyl-transferases and uses thereof
SG11201502069SA (en) Beta-hydroxy-beta-methylbutryic acid- containing compositions and uses thereof
GB201208315D0 (en) Pharmaceutical methods and compositions
EP2838365A4 (en) ANTIMICROBIAL COMPOSITIONS AND USES THEREOF
SI2830587T1 (sl) Sestavek za zaščito in uravnoteženje kože
GB201215414D0 (en) Composition and use